Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Posts Earnings Results

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) released its quarterly earnings results on Tuesday, August 7th. The medical equipment provider reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01), Bloomberg Earnings reports. The firm had revenue of $1.67 million for the quarter, compared to analysts’ expectations of $3.00 million. Corindus Vascular Robotics had a negative net margin of 323.84% and a negative return on equity of 110.93%.

CVRS traded up $0.01 during trading on Friday, hitting $1.09. The company’s stock had a trading volume of 304,800 shares, compared to its average volume of 1,029,320. Corindus Vascular Robotics has a one year low of $0.66 and a one year high of $1.97.

Several equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Corindus Vascular Robotics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 14th. Stifel Nicolaus downgraded shares of Corindus Vascular Robotics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $3.00 to $1.00 in a research note on Wednesday, August 8th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Corindus Vascular Robotics in a research note on Monday, May 21st. They set a “buy” rating and a $2.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $1.50.

In other news, Director Louis A. Cannon acquired 30,000 shares of Corindus Vascular Robotics stock in a transaction dated Friday, August 24th. The stock was purchased at an average cost of $1.02 per share, with a total value of $30,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Louis A. Cannon acquired 31,000 shares of Corindus Vascular Robotics stock in a transaction dated Monday, August 13th. The stock was purchased at an average cost of $0.96 per share, with a total value of $29,760.00. The disclosure for this purchase can be found here. Insiders acquired 91,000 shares of company stock worth $90,060 over the last quarter.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures.

Recommended Story: Book Value Per Share – BVPS

Earnings History for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply